DOM-CIPROFLOXACIN TABLET

Country: Կանադա

language: անգլերեն

source: Health Canada

buyitnow

SPC SPC (SPC)
10-09-2019

active_ingredient:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)

MAH:

DOMINION PHARMACAL

ATC_code:

J01MA02

INN:

CIPROFLOXACIN

dosage:

100MG

pharmaceutical_form:

TABLET

composition:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 100MG

administration_route:

ORAL

units_in_package:

100

prescription_type:

Prescription

therapeutic_area:

QUINOLONES

leaflet_short:

Active ingredient group (AIG) number: 0123207005; AHFS:

authorization_status:

APPROVED

authorization_date:

2004-03-24

SPC

                                PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
DOM-CIPROFLOXACIN
(Ciprofloxacin Hydrochloride Tablets, USP)
100 mg, 250 mg, 500 mg and 750 mg
ANTIBACTERIAL AGENT
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100,
Montréal, Quebec
H4P 2T4 DATE OF REVISION: SEPTEMBER 10, 2019
SUBMISSION CONTROL NO.: 229111
_Dom-CIPROFLOXACIN Product Monograph _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
6
WARNINGS AND PRECAUTIONS
............................................................................................
6
ADVERSE REACTIONS
............................................................................................................
11
DRUG INTERACTIONS
............................................................................................................
14
DOSAGE AND ADMINISTRATION
........................................................................................
19
OVERDOSAGE
...........................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
21
STORAGE AND STABILITY
....................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
25
PHARMACEUTICAL INFORMATION
..........................................................................
                                
                                read_full_document
                                
                            

documents_in_other_languages

SPC SPC ֆրանսերեն 10-09-2019